Because JS207 exhibits high affinity for human VEGFA, intravenous administration is expected to result in the rapid formation of a JS207/VEGFA complex in circulation prior to its engagement with PD-1 within the tumor microenvironment. Here, VEGFA is linked to neoplasm.